Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Jorge E. Cortes, Michael W. Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F. Apperley
Institutions: Federal Almazov North-West Medical Research Centre, Hospital Ramos Mejía, Hospital del Salvador, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Princess Margaret Cancer Centre, Hackensack University Medical Center, Jena University Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, King's College Hospital, National Medical Research Center for Hematology, Nebraska Medical Center, University of Nebraska Medical Center, University of Michigan, U-M Rogel Cancer Center, Takeda (United States), Imperial College London
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310105218